Patents Assigned to Trellis Bioscience, LLC
  • MONOCLONAL ANTIBODIES TARGETING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) FAMILY SIGNALING
    Publication number: 20180002420
    Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 4, 2018
    Applicant: Trellis Bioscience, LLC
    Inventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN
    Publication number: 20170204165
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 20, 2017
    Applicant: Trellis Bioscience, LLC
    Inventors: Lawrence M. KAUVAR, Stote ELLSWORTH, William USINGER, Krista Maureen MCCUTCHEON, Ying-Ping JIANG, Fen ZHANG, Bo CHEN, Gizette SPERINDE, Minha PARK, Orit FOORD
  • High affinity human antibodies to human cytomegalovirus (CMV) GB protein
    Patent number: 9688744
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 27, 2017
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • BINDING MOIETIES FOR BIOFILM REMEDIATION
    Publication number: 20160237145
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 18, 2016
    Applicant: Trellis Bioscience, LLC
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON
  • Antibodies immunoreactive with heregulin-coupled HER3
    Patent number: 9321839
    Abstract: Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses HER3.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: April 26, 2016
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
  • High affinity human antibodies to human cytomegalovirus (CMV) gB protein
    Patent number: 9017668
    Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: April 28, 2015
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Antibodies immunoreactive with heregulin-coupled HER3
    Patent number: 8828388
    Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: September 9, 2014
    Assignee: Trellis Bioscience, LLC
    Inventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
  • ANTIBODIES IMMUNOREACTIVE WITH HEREGULIN-COUPLED HER3
    Publication number: 20130122000
    Abstract: Antibodies which specifically bind heregulin-coupled HERS, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.
    Type: Application
    Filed: January 17, 2013
    Publication date: May 16, 2013
    Applicant: Trellis Bioscience, LLC
    Inventor: Trellis Bioscience, LLC
  • Antibodies immunoreactive with heregulin-coupled HER3
    Patent number: 8362215
    Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: January 29, 2013
    Assignee: Trellis Bioscience, LLC
    Inventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen